Can Arthritis Light Up on a PSMA PET Scan?
Yes, arthritis and other benign musculoskeletal conditions can show increased PSMA uptake on PET scans, creating potential false-positive findings that must be differentiated from prostate cancer metastases.
Mechanism of PSMA Uptake in Benign Bone Conditions
PSMA is not truly "prostate-specific" despite its name—it is expressed in multiple tissues beyond the prostate, including normal bone and areas of increased bone turnover 1. Benign musculoskeletal conditions demonstrate PSMA uptake through mechanisms related to:
- Increased bone metabolism and remodeling at sites of degenerative change, fractures, and inflammatory arthropathies 1
- Neovascularization in areas of active bone repair and inflammation 1
- Upregulation of folate hydrolase activity in reactive bone processes 2
Specific Benign Conditions That Show PSMA Uptake
The following musculoskeletal conditions are well-documented to cause false-positive PSMA uptake 1:
- Fractures (acute and healing)
- Osteodegenerative changes including osteoarthritis
- Fibrous dysplasia
- Paget's disease (which can show diffuse increased uptake with SUVmax values around 9, as demonstrated in clinical cases) 2
- Inflammatory arthropathies (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) 3
Critical Differentiation Strategy
Radiologists must fully analyze morphologic features on unfused CT images to correctly interpret PSMA-positive findings and avoid misdiagnosis 1. The differentiation approach includes:
CT Morphology Assessment
- Benign degenerative changes show characteristic osteophytes, joint space narrowing, subchondral sclerosis, and preserved cortical margins on CT 1
- Metastatic disease typically demonstrates cortical destruction, soft tissue masses, or pathologic fractures 1
- Paget's disease shows mixed osteosclerotic/osteolytic lesions with bone expansion 2
SUVmax Values
- While metastatic lesions often show high SUVmax (mean 16.57±23.59 in one series), benign conditions can also demonstrate elevated uptake 2
- SUVmax alone cannot reliably distinguish benign from malignant uptake—morphologic correlation is essential 1
Dual-Phase Imaging
- Early (60 minutes) and late (180 minutes) post-injection imaging can help differentiate benign from malignant uptake patterns 2
- Persistent or increasing uptake on delayed imaging may favor malignancy, though this is not absolute 2
Clinical Context Matters
The interpretation of PSMA-positive bone lesions must consider 4, 5:
- Patient's PSA level and kinetics (higher PSA correlates with higher likelihood of true metastases)
- Gleason score and risk stratification (higher grade disease more likely to metastasize)
- Distribution pattern (multiple random lesions favor metastases; isolated uptake at typical degenerative sites favors benign disease)
- Prior imaging for comparison
Common Pitfalls to Avoid
The most critical error is assuming all PSMA-positive bone lesions represent metastatic disease without CT correlation 1. Additional pitfalls include:
- Overlooking typical degenerative patterns on CT that explain PSMA uptake 1
- Failing to recognize physiologic PSMA uptake in ganglia, salivary glands, kidneys, liver, and small intestine 2
- Not considering that 5-10% of prostate cancers are PSMA-negative, particularly poorly differentiated variants 6
When Additional Imaging Is Needed
If PSMA PET findings remain equivocal after CT correlation 7, 1:
- MRI provides superior soft tissue characterization and can identify bone marrow edema patterns
- Comparison with prior bone scans or other PET tracers (if available) may clarify chronicity
- Short-interval follow-up imaging (3-6 months) can distinguish progressive metastatic disease from stable degenerative changes
- Biopsy remains the gold standard when diagnosis impacts treatment decisions
Practical Recommendation
Always interpret PSMA PET in conjunction with the unfused CT images and clinical context 1. When isolated PSMA uptake occurs at typical sites of degenerative disease (spine facet joints, sacroiliac joints, large joint osteoarthritis) with corresponding degenerative CT changes and low clinical suspicion, these findings likely represent benign uptake rather than metastases 1, 2.